These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 35732349)

  • 1. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
    Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
    Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
    Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.
    Sei S; Ahadova A; Keskin DB; Bohaumilitzky L; Gebert J; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Front Oncol; 2023; 13():1147590. PubMed ID: 37035178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
    Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
    Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immune Biology of Microsatellite-Unstable Cancer.
    Kloor M; von Knebel Doeberitz M
    Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
    Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N
    Front Immunol; 2021; 12():757804. PubMed ID: 34630437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
    Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
    Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
    Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
    Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
    Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
    Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.
    Bolivar AM; Duzagac F; Sinha KM; Vilar E
    Mol Aspects Med; 2023 Oct; 93():101204. PubMed ID: 37478804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
    Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
    J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a vaccine to prevent cancer in Lynch syndrome patients.
    von Knebel Doeberitz M; Kloor M
    Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
    Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
    JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.